Current Edition


For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
Aduhelm (aducanumab)

Amid Aduhelm’s rocky launch, Biogen eyes large-scale layoffs

Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …

Continue Reading →

GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms

The future of ViiV Healthcare’s HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around £2 billion ($2.65 billion) …

Continue Reading →